The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: Rationale, results and future horizons

Fundamental and Clinical Pharmacology

Volumn 21, Issue SUPPL. 2, 2007, Pages 41-43

  Di Sciascio, Germano ^a  

^a UNIVERSITY OF ROME   (Italy)

Author keywords

Angioplasty; Atorvastatin; Coronary intervention

Indexed keywords

ATORVASTATIN; PLACEBO;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOPLASTY; BOLUS INJECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; ITALY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT OUTCOME;

ANGINA PECTORIS; ANGIOPLASTY; CARDIOMYOPATHIES; FORECASTING; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 36248968761     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00539.x     Document Type: Review

References (16)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344 1383 1389.
2. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333 1301 1307.
3. Pasceri V., Patti G., Nusca A. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation (2004) 110 674 678.
4. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment improves outcome in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-acute coronary syndromes) randomized trial. J. Am. Coll. Cardiol. (2007) 49 1272 1278.
5. Wassmann S., Faul A., Hennen B. et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ. Res. (2003) 93 e98 e103.
6. Hinoi T., Matsuo S., Tadehara F., Tsujiyama S., Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am. J. Cardiol. (2005) 96 89 91.
7. Sanguigni V., Pignatelli P., Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation (2005) 111 412 419.
8. Patti G., Pasceri V., Nusca A. et al. Atorvastatin therapy reduces markers of myocardial damage after percutaneous coronary interventions? Preliminary data from a randomised study J. Am. Coll. Cardiol. (2004) 44 (Suppl. A) 447.
9. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. (2003) 41 508 515.
10. Patti G., Chello M., Pasceri V. et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention. Results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. J. Am. Coll. Cardiol. (2006) 48 1560 1566.
11. Bonetti P.O., Lerman L.O., Napoli C., Lerman A. Statin effects beyond lipid lowering. Are they clinically relevant? Eur. Heart J. (2003) 24 225 248.
12. Chello M., Carassiti M., Agrò F. et al. Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2004) 18 605 609.
13. Lanza G.A., Sgueglia G.A., Cianflone D. et al., SPAI (Stratificazione Prognostica dell'Angina Instabile) Investigators. Relation of heart rate variability to serum levels of C-reactive protein in patients with unstable angina pectoris. Am. J. Cardiol. (2006) 97 1702 1706.
14. Patti G., Chello M., Candura D. et al. A randomized trial of atorvastatin for reduction of post-operative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study. Circulation (2006) 114 1455 1461.
15. Patti G., Chello M., Candura D. et al. Response letter regarding article 'a randomized trial of atorvastatin for reduction of post-operative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study'. Circulation (2007) 115 405.
16. Mensah K., Mocanu M.M., Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J. Am. Coll. Cardiol. (2005) 45 1287 1291.